^
    22d
    MED20-165: Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
    P1, N=12, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jan 2026 --> Jan 2027 | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial completion date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule)
    |
    Iomab-B (I-131-apamistamab)
    3ms
    Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML (RADAR) (clinicaltrials.gov)
    P2/3, N=306, Not yet recruiting, Actinium Pharmaceuticals
    New P2/3 trial
    |
    cyclophosphamide • fludarabine IV • Iomab-B (I-131-apamistamab)
    6ms
    131I-apamistamab-based Conditioning for Hematopoietic Stem Cell Transplant (HSCT) in Advanced Sickle Cell Disease (SCD) (clinicaltrials.gov)
    P1, N=24, Recruiting, Columbia University
    New P1 trial
    |
    Campath (alemtuzumab) • sirolimus • Iomab-B (I-131-apamistamab)
    6ms
    NCI-2018-01788: 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov)
    P1/2, N=30, Recruiting, Fred Hutchinson Cancer Center | Trial primary completion date: May 2024 --> Jun 2027
    Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B)
    |
    cyclophosphamide • fludarabine IV • Iomab-B (I-131-apamistamab)
    6ms
    Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases (clinicaltrials.gov)
    P1/2, N=40, Recruiting, Fred Hutchinson Cancer Center | Suspended --> Recruiting
    Enrollment open
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    cyclophosphamide • sirolimus • fludarabine IV • Iomab-B (I-131-apamistamab)
    7ms
    NCI-2018-01788: 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov)
    P1/2, N=30, Recruiting, Fred Hutchinson Cancer Center | Trial primary completion date: Jun 2027 --> May 2024
    Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B)
    |
    cyclophosphamide • fludarabine IV • Iomab-B (I-131-apamistamab)
    7ms
    Study of IOMAB-ACT Followed by CAR-T Cell Therapy for Patients Relapsed or Refractory (Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P1/2, N=30, Recruiting, University of Texas Southwestern Medical Center | Not yet recruiting --> Recruiting | Trial completion date: May 2029 --> May 2030 | Trial primary completion date: May 2028 --> May 2029
    Enrollment open • Trial completion date • Trial primary completion date
    |
    Iomab-B (I-131-apamistamab) • apamistamab-I-131 (Iomab-ACT)
    7ms
    Study of IOMAB-ACT Followed by CAR-T Cell Therapy for Patients Relapsed or Refractory (Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P1/2, N=30, Not yet recruiting, University of Texas Southwestern Medical Center | Initiation date: Apr 2025 --> Jul 2025
    Trial initiation date
    |
    Iomab-B (I-131-apamistamab) • apamistamab-I-131 (Iomab-ACT)
    10ms
    NCI-2018-01788: 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov)
    P1/2, N=30, Recruiting, Fred Hutchinson Cancer Center | Trial completion date: Mar 2027 --> Mar 2029 | Trial primary completion date: Jun 2025 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B)
    |
    cyclophosphamide • fludarabine IV • Iomab-B (I-131-apamistamab)
    11ms
    Study of IOMAB-ACT Followed by Yescarta for Patients Relapsed or Refractory (Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P1/2, N=30, Not yet recruiting, University of Texas Southwestern Medical Center
    New P1/2 trial
    |
    Yescarta (axicabtagene ciloleucel) • Iomab-B (I-131-apamistamab) • apamistamab-I-131 (Iomab-ACT)
    over1year
    Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases (clinicaltrials.gov)
    P1/2, N=40, Suspended, Fred Hutchinson Cancer Center | Recruiting --> Suspended
    Trial suspension
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    HLA-A*02
    |
    cyclophosphamide • sirolimus • fludarabine IV • Iomab-B (I-131-apamistamab)
    almost2years
    NCI-2018-01788: 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov)
    P1/2, N=30, Recruiting, Fred Hutchinson Cancer Center | Trial completion date: Oct 2025 --> Mar 2027 | Trial primary completion date: Jan 2024 --> Jun 2025
    Trial completion date • Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B)
    |
    cyclophosphamide • fludarabine IV • Iomab-B (I-131-apamistamab)